~~<i id='E8D957D12F'><strike id='E8D957D12F'><tt id='E8D957D12F'><pre id='E8D957D12F'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：entertainment 2025-09-30 06:12:06 Page View：3559

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Stanford updates investigation of president’s past research
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

3:53AuthoritiessearchthehomeofsuspectRexHeuermann,July18,2023,inMassapequaPark,N.Y.JohnMinchillo/APR

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

What to do when lifesaving products contribute to climate change

AdobeManycommonlysuggestedwaystoaddressclimatechangepresentfewethicalchallenges:Cutfossilfuels.Eatle